Prognostic significance of substage and WHO classification systems in T1 urothelial carcinoma of the bladder

Current Opinion in Urology

Volumn 25, Issue 5, 2015, Pages 427-435

  Van De Putte, Elisabeth E Fransen ^a   Behrendt, Mark A ^a,b   Pigot, Garry L S ^a,c   Van Der Kwast, Theo H ^d   Van Rhijn, Bas W G ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Grade; Progression; Substage; T1; Urinary bladder cancer

Indexed keywords

BLADDER CARCINOMA; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; GOLD STANDARD; HUMAN; INVASIVE CARCINOMA; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; PATHOLOGIST; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; RELIABILITY; REVIEW; TRANSITIONAL CELL CARCINOMA; TUMOR INVASION; WORLD HEALTH ORGANIZATION; CARCINOMA; CLASSIFICATION; DISEASE COURSE; DISEASE FREE SURVIVAL; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROTHELIUM;

CARCINOMA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84942597877     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0000000000000202     Document Type: Review

References (81)

1. Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005; 66:4-34.
2. Nieder AM, Brausi M, Lamm D, et al. Management of stage T1 tumors of the bladder: international consensus panel. Urology 2005; 66:108-125.
3. Martin-Doyle W, Leow J, Orsola A, et al. Improving selection criteria for early cystectomy in h igh-grade T1 bladder cancer: a meta-Analysis of 15,215 patients. J Clin Oncol 2015; 33:643-650.
4. Stein JP,Penson DF. Invasive T1 bladder cancer: indications and rationale for radical cystectomy. BJU Int 2008 102 270-275.
5. Sternberg I, Paz K, Gal E, et al. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection. BJU Int 2013; 112:54-59.
6. Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors J Urol 2001; 166:1296-1299.
7. Cookson MS, Chang SS, Wells N, et al. Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease. J Urol 2003; 169:101-104.
8. van Rhijn B, Burger M, Lotan Y, et al. Recurrence and progression of disease in nonmuscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009; 56:430-442.
9. Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder: update. Eur Urol 2013; 64:639-653.
10. Sylvester R, van der Meijden A, Oosterlink W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49:466-477.
11. Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 2009; 182:2195-2203.
12. Compérat E, Egevad L, Lopez-Beltran A, et al. An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps. Histopathology 2013; 63:756-766.
13. van Rhijn BWG, van der Kwast TH, Kakiashvili DM, et al. Pathological stage reviewis indicated in primary pT1bladder cancer.BJUInt 2010; 106:206-211.
14. Xylinas E, Kent M, Kluth L, et al. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in nonmuscle-invasive urothelial carcinoma of the bladder. Br J Cancer 2013; 109:1460-1466.
15. van Rhijn BWG, Liu L, Vis AN, et al. Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. BJU Int 2012; 110:1169-1176.
16. Hansel D, Amin M, Comperat E, et al. A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. Eur Urol 2013; 63:321-332.
17. Cheng L, Montironi R, Davidson D, Lopez-Beltran A. Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol 2009; 22:S70-S95.
18. Abel P, Henderson D, BennetM, et al. Differing interpretations by pathologists of the pT category and grade of transitional cell cancer of the bladder. Br J Urol 1988; 62:339-342.
19. Witjes J, Kiemeney L, Schaafsma H, et al. The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. Br J Urol 1994; 73:172-176.
20. Tosoni I, Wagner U, Sauter G, et al. Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer. BJU Int 2000; 85:48-53.
21. van der Meijden A, Sylvester R, Collette L, et al. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research an d Treatment. J Urol 2000; 164:1533-1537.
22. Bol M, Baak J, Buhr-Wildhagen S, et al. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial ca rcinoma of the bladder. J Urol 2003; 169:1291-1294.
23. Witjes J, Moonen P, Heijden A, Van Der. Review pathology in a diagnostic bladder cancer trial: effect of patient risk category. Urology 2006; 67:751-755.
24. Herr H, Donat S. Quality control in transurethral resection of bladder tumours. BJU Int 2008; 102:1242-1246.
25. Jakse G,Algaba F,Malmström P,Oosterlinck W A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol 2004 45 539-546.
26. Mariappan P, Zachou A, Grigor K. Detrusor Muscle in the First, apparently complet e transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent. Eur Urol 2010; 57:843-849.
27. Ro JY, Ayala AG, El-Na ggar A. Muscularis mucosa of urinary bladder, importance for staging and treatment. Am J Surg Pathol 1987; 11:668-673.
28. Dixon J, Gosling J. Histology and fine structure of the muscularis mucosae of the human urinary bladder. J Anat 1983; 136:265-271.
29. Younes M, Sussman J, True L. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma o f the urinary bladder. Cancer 1990; 66:543-548.
30. Hasui Y, Osada Y, Kitada S, Nishi S. Significance of invasion to the muscularis mucosae on the progression of superficial bladder cancer. Urology 1994; 43:782-786.
31. Angulo J, Lopez J, Grignon D, Sanchez-Chapado M. Muscularis mucosa differentiates two populations with different prognosis in stage T1 bladder cancer. Urology 19 95; 45:47-53.
32. Platz CE, Cohen MB, Jones MP, et al. Is microstaging of early invasive cancer of the urinary bladder possible or useful? Mod Pathol 1996; 9:1035-1039.
33. Holmang S, Hedelin H, Anderstrom C, et al. The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. J Urol 1997; 157:800-804.
34. Smits G, Sc haafsma E, Kiemeney L, et al. Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risk of progression. Urology 1998; 52:1009-1014.
35. Hermann G, Horn T, Steven K. The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. J Urol 1998; 159:91-94.
36. Cheng BL, Neumann RM, Weaver AL, et al. Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol 1999; 17:3182-3187.
37. Kondyl is FI, Demirci S, Ladaga L, et al. Outcomes after intravesical bacillus calmette-guerin are not affected by substaging of high grade T1 transitional cell carcinoma. J Urol 2000; 163:1120-1123.
38. Shariat SF, Weizer AZ, Green A, et al. Prognostic value of p53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology 2000; 56:735-740.
39. Bernardini S, Billerey C, Martin M, et al. The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma. J Urol 2001; 165:42-46.
40. . Sozen S, Akbal C, Sokmensuer C, et al. Microstaging of pT1 transitional cell carcinoma of the bladder. Urol Int 2002; 69:200-206.
41. Orsola A, Trias I, Raventos C, et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol 2005; 48:231-238.
42. Andius P, Johansson S, Holmäng S. Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Urology 2007; 70:758-762.
43. Mhawech-fauceglia P, Fischer G, Alvarez V Jr., et al. Predicting outcome in minimally invasive (T1a and T1b) urothelial bladder carcinoma using a panel of biomarkers: a high throughput tissue microarray analysis. BJU Int 2007; 100:1182-1187.
44. Orsola A, Cecchini L, Raventós C, et al. Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette. BJU Int 2009; 105:202-207.
45. Bertz S, Denzinger S, Otto W, et al. Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bl adder cancer-evaluation of a large hospital-based single-centre series. Histopathology 2011; 59:722-732.
46. Lee JY, Joo HJ, Cho DS, et al. Prognostic significance of substaging according to the depth of lamina propria invasion in primary T1 transitional cell carcinoma of the bladder. Korean J Urol 2012; 53:317-323.
47. van Rhijn BWG,van der Kwast TH,Alkhateeb SS,et al. A new and highly prognostic system to discern T1 bladder cancer substage Eur Urol 2012 61 378-384.
48. Chang W-C, Chang Y-H, Pan C-C. Prognostic significance in substaging of T1 urinary bladder urothelial carcinoma on transurethral resection. Am J Surg Pathol 2012; 36:454-461.
49. Palou J, Sylvester R, Faba O, et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treate d with bacillus Calmette. Eur Urol 2012; 62:118-125.
50. Rouprět M, Seisen T, Compérat E, et al. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive blad der carcinoma: French national multicenter study with central pathology review. J Urol 2013; 189:2069-2076.
51. Brimo F, Wu C, Zeizafoun N, et al. Prognostic factors in T1 bladder urothelial carcinom a: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion. Hum Pathol 2013; 44:95-102.
52. Olsson H, Hultman P, Rosell J, Jahnson S. Population-based study on prognostic factors for recurrence and progression in primary stage T1 bladder tumours. Scand J Urol 2013; 47:188-195.
53. Soukup V, Dusková J, Pesl M, et al. The prognostic value of T1 bladder cancer substaging: a single institution retrospective study. Urol Int 2014; 92:150-156.
54. de Marco V, Cerruto M, D'Elia C, et al. Prognostic role of substaging in T1G3 transitional cell carcinoma of the urinary bladder. Mol Clin Oncol 2014; 2:575-580.
55. Orsola a, Werner L, de Torres I, et al. Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients. Br J Cancer 2015; 112:468-474. This is the only pros pective study investigating the prognostic value of T1a/b substage based on muscularis mucosae invasion. Although 5-year CSS rates were high for both substages, stage T1b tumors had a significantly higher progression rate than T1a-BC.
56. Patschan O, Sjodahl G, Chebil G, et al. A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma. Eur Urol 2015; (in press). Apart from investigating the prosnotic value of T1a/b substage based on mus cularis mucosae invasion, this study associated T1-BC progression to mulecular subtype.
57. Keep JC, Piehl M, Miller A, Oyasu R. Invasive carcinomas of the urinary bladder. Evaluation of tunica muscularis mucosae involvement. Am J Clin Pathol 1989; 91:575-579.
58. Cottrell L, Nairn E, Hair M. Consistency of microstaging pT1 bladder transitional cell carcinoma. J Clin Pathol 2007; 60:735-736.
59. Segal R, Yafi F, Brimo F, et al. Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy? BJU Int 2012; 109:1026-1030.
60. Paner G, Ro J, Wojcik E, et al. Further characterization of the muscle layers and lamina propria of the urinary bladder by systematic histologic mapping: implications for pathologic staging of invasive urothelial carcin oma. Am J Surg Pathol 2007; 31:1420-1429.
61. van der Aa MNM, van Leenders GJLH, Steyerberg EW, et al. A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation. Hum Pathol 2005; 36:981-986.
62. Nishiyama N, Kitamura H, Maeda T, et al. Clinicopathological analysis of patients with nonmuscle-invasive bladder cancer: Prognostic value and clinical reliability of the 2004 WHO classification system. Jpn J Clin Oncol 2013; 43:1124-1131.
63. Cheng L, Weaver A, Neumann R, et al. Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer. Cancer 1999; 86:1035-1043.
64. Mostofi FK, Sobin LH, Torloni H. Histological classification of urinary bladder tumours. In: Histological typing of urinary bladder tumours. International Classification of Tumours, No 10. Geneva: World Health Organisation; 1973. pp. 21-31.
65. Yorukoglu K, Tuna B, Dikicioglu E, et al. Reproducibility of the 1998 World Health Organization/International Society of Urologic Pathology classification of papillary urothelial neoplasms of the urinary blad der. Virchows Arch 2003; 443:734-740.
66. van Rhijn BWG, van Leenders GJLH, Ooms BCM, et al. The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer gr ading. Eur Urol 2010; 57:1052-1057.
67. Eble JN, Sauter GEJ, Epstein JI, et al. World health organization classification of tumours: pathology and genetics of tumours of the urinary system and m ale genital organs. Lyon: IARC Press; 2004.
68. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22:1435-1448.
69. MacLennan GT, Kirkali Z, Cheng L. Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol 2007; 51:889-897.
70. Kulkarni GS,Hakenberg OW,Gschwend JE,et al. An updated critical analysis of the treatment strategy for newly diagnosed high-g rade T1 (Previously T1G3) bladder cancer Eur Urol 2010 57 60-70.
71. Malmström PU, Busch C, Norlén BJ. Recurrence, progression and survival in bladder cancer. A retrospective analysis of 232 pat ients with greater than or equal to 5-year follow-up. Scand J Urol Nephrol 1987; 21:185-195.
72. Busch C, Algaba F. The WHO/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems. Virchows Arch 2002; 441:105-108.
73. Liedberg F, Lauss M, Patschan O, et al. The importance of being grade 3: WHO1999 versusWHO2004 pathologic grading. Eur Urol 2012; 62:620-623.
74. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007; 178:2314-2330.
75. van Rhijn BWG, Musquera M, Liu L, et al. Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications. Mod Pathol 2015; 28:695-705.
76. May M, Brookman-Amissah S, Roigas J, et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol 2010; 57:850-858.
77. Kamel MH, Daly PJ, Khan MF, et al. Survival and progression in high grade tumour subset of G2 and G3 pT1 bladder transitional cell carcinoma. Eur J Surg Oncol 2006; 32:1139-1143.
78. Otto W, Denzinger S, Fritsche H-M, et al. The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int 2011; 107:40 4-408.
79. Pellucchi F, Freschi M, Moschini M, et al. Oncological predictive value of the 2004 World Health Organisation grading classification in primary T1 nonmuscle-invasive bladder cancer. A step forward or back? BJU Int 2014; 115:267-273.
80. Kwak C, Ku JH, Park J-Y, et al. Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer. J Ur ol 2004; 171:149-152.
81. Burger M, Denzinger S, Wieland W-F, et al. Does the current World Health Organization classification predict the outcome better in patients with noninvasive bladder canc er of early or regular onset? BJU Int 2008; 102:194-197.